What is the usual Cosentyx (secukinumab) dose for each approved condition?
Cosentyx dosing depends on the disease being treated and, in some cases, the patient’s weight does not change the dose.
For plaque psoriasis (adult), the recommended regimen is:
- 300 mg once weekly for 5 weeks, then
- 300 mg every 4 weeks thereafter [1].
For psoriatic arthritis (PsA), the recommended regimen is:
- 150 mg once every 4 weeks, or
- 300 mg once every 4 weeks if needed (based on clinical response) [1].
For ankylosing spondylitis (AS), the recommended regimen is:
- 150 mg once every 4 weeks, or
- 300 mg once every 4 weeks if needed (based on clinical response) [1].
For non-radiographic axial spondyloarthritis, the recommended regimen is:
- 150 mg once every 4 weeks, or
- 300 mg once every 4 weeks if needed (based on clinical response) [1].
For hidradenitis suppurativa (HS), the recommended regimen is:
- 300 mg once weekly for the first 5 weeks, then
- 300 mg every 4 weeks thereafter [1].
For pediatric plaque psoriasis, dosing depends on body weight:
- For patients < 50 kg: 150 mg once weekly for 5 weeks, then 150 mg every 4 weeks [1]
- For patients ≥ 50 kg: 300 mg once weekly for 5 weeks, then 300 mg every 4 weeks [1].
How does the loading dose work (when you start Cosentyx)?
In multiple conditions that use a loading phase (for example, psoriasis and hidradenitis suppurativa), patients receive a higher frequency schedule at the start:
- Weekly dosing for 5 weeks, then
- Maintenance dosing every 4 weeks [1].
Some other indications (notably several forms of axial disease and psoriatic arthritis) may start at 150 mg or 300 mg every 4 weeks, with adjustments based on response rather than a weekly loading phase [1].
What dose changes are considered “needed” for 150 mg vs 300 mg?
Cosentyx guidance distinguishes 150 mg vs 300 mg as alternative dosing regimens for certain inflammatory conditions. The dosing can move to the higher regimen based on clinical response [1]. Exact step-up timing and how clinicians decide depends on the indication and the patient’s response.
What information do clinicians usually check before dosing?
Common checks include:
- The approved indication (plaque psoriasis vs PsA vs AS vs axial spondyloarthritis vs HS)
- Whether the patient is a pediatric patient (weight-based dosing applies in pediatric plaque psoriasis) [1]
- Whether dosing should be 150 mg or 300 mg based on response for applicable indications [1]
Source
- DrugPatentWatch.com – Cosentyx (secukinumab) dosing information